Cargando…
Bone lesion absorbed dose profiles in patients with metastatic prostate cancer treated with molecular radiotherapy
OBJECTIVE: The aim of this study was to calculate the range of absorbed doses that could potentially be delivered by a variety of radiopharmaceuticals and typical fixed administered activities used for bone pain palliation in a cohort of patients with metastatic castration-resistant prostate cancer...
Autores principales: | Denis-Bacelar, Ana M, Chittenden, Sarah J, McCready, V Ralph, Divoli, Antigoni, Dearnaley, David P, O’Sullivan, Joe M, Johnson, Bernadette, Flux, Glenn D |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The British Institute of Radiology.
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5966004/ https://www.ncbi.nlm.nih.gov/pubmed/29293372 http://dx.doi.org/10.1259/bjr.20170795 |
Ejemplares similares
-
A radiobiological model of metastatic burden reduction for molecular radiotherapy: application to patients with bone metastases
por: Denis-Bacelar, Ana M, et al.
Publicado: (2017) -
Phase I/II trials of (186)Re-HEDP in metastatic castration-resistant prostate cancer: post-hoc analysis of the impact of administered activity and dosimetry on survival
por: Denis-Bacelar, Ana M., et al.
Publicado: (2016) -
High activity Rhenium-186 HEDP with autologous peripheral blood stem cell rescue: a phase I study in progressive hormone refractory prostate cancer metastatic to bone
por: O'Sullivan, J M, et al.
Publicado: (2002) -
Opportunities for research in molecular radiotherapy
por: Flux, Glenn D, et al.
Publicado: (2017) -
Uncertainty analysis of tumour absorbed dose calculations in molecular radiotherapy
por: Finocchiaro, Domenico, et al.
Publicado: (2020)